| CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/4985 (2013.01); A61K 47/02 (2013.01)] | 11 Claims |
|
1. A process for preparing a solution comprising (I), (II), or (III):
(I):
(a) a compound having the formula (I):
![]() (b) NaH2PO4·2H2O and Na2HPO4·2H2O; and optionally
(c) NaCl;
wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the solution is chosen such that:
(i) the molar ratio of NaH2PO4·2H2O to compound (I) is in the range of from 0.02 to 0.50; and
(ii) the molar ratio of Na2HPO4·2H2O to compound (I) is in the range of from 0.02 to 0.50; and
wherein the solution is adapted for administration by infusion or injection; or
(II):
(a) a compound having the formula (II):
![]() (b) NaH2PO4·2H2O and Na2HPO4·2H2O; and optionally
(c) NaCl;
wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the solution is chosen such that:
(i) the molar ratio of NaH2PO4·2H2O to compound (II) is in the range of from 0.02 to 0.50; and
(ii) the molar ratio of Na2HPO4·2H2O to compound (II) is in the range of from 0.02 to 0.50; and
wherein the solution is adapted for administration by infusion or injection; or
(III):
(a) a compound having the formula (I):
![]() (b) a compound having the formula (II):
![]() (c) NaH2PO4·2H2O and Na2HPO4·2H2O; and optionally
(d) NaCl;
wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the solution is chosen such that:
(i) the molar ratio of NaH2PO4·2H2O to compound (I) is in the range of from 0.02 to 0.50; and
(ii) the molar ratio of Na2HPO4·2H2O to compound (I) is in the range of from 0.02 to 0.50; and
wherein the solution is adapted for administration by infusion or injection;
wherein the process comprises the following steps:
(1) preparing a buffer comprising NaH2PO4·2H2O and Na2HPO4·2H2O by:
(a) dissolving NaH2PO4·2H2O in water, to form a first solution;
(b) dissolving Na2HPO4·2H2O in water, to form a second solution;
(c) adding the first NaH2PO4·2H2O solution formed in step (a) above to the second Na2HPO4·2H2O solution formed in step (b) above, to form a third sodium phosphate solution having a pH of 7.4; and
(d) adding the third sodium phosphate solution formed in step (c) above to a 5N NaOH solution, to form the buffer comprising NaH2PO4·2H2O and Na2HPO4·2H2O;
(2) dissolving a compound of formula (II):
![]() in the buffer comprising NaH2PO4·2H2O and Na2HPO4·2H2O prepared in step (1) above, to form a fourth solution; or
(2) dissolving a compound of formula (III):
![]() in the buffer comprising NaH2PO4·2H2O and Na2HPO4·2H2O prepared in step (1) above, to form a fourth solution; or
(2) dissolving a compound of formula (II):
![]() and a compound of formula (III):
![]() in the buffer comprising NaH2PO4·2H2O and Na2HPO4·2H2O prepared in step (1) above, to form a fourth solution;
(3) lyophilizing the fourth solution formed in step (2) above, to form a lyophilisate;
(4) filling the lyophilisate formed in step (3) above into a vial; and
(5) reconstituting the lyophilisate of step (4) above in a pharmaceutically acceptable fluid, to prepare a fifth solution comprising (I), (II), or (III) above that is adapted for administration by infusion or injection.
|